CN117241817A - 包含环状肽化合物的制剂及其制备方法 - Google Patents

包含环状肽化合物的制剂及其制备方法 Download PDF

Info

Publication number
CN117241817A
CN117241817A CN202280029838.6A CN202280029838A CN117241817A CN 117241817 A CN117241817 A CN 117241817A CN 202280029838 A CN202280029838 A CN 202280029838A CN 117241817 A CN117241817 A CN 117241817A
Authority
CN
China
Prior art keywords
compound
composition
formulation
added
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280029838.6A
Other languages
English (en)
Chinese (zh)
Inventor
植户隆充
久保木友香理
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117241817A publication Critical patent/CN117241817A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280029838.6A 2021-05-07 2022-05-06 包含环状肽化合物的制剂及其制备方法 Pending CN117241817A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-079015 2021-05-07
JP2021079015 2021-05-07
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Publications (1)

Publication Number Publication Date
CN117241817A true CN117241817A (zh) 2023-12-15

Family

ID=83932759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280029838.6A Pending CN117241817A (zh) 2021-05-07 2022-05-06 包含环状肽化合物的制剂及其制备方法

Country Status (12)

Country Link
US (1) US20240366711A1 (enExample)
EP (1) EP4299069A4 (enExample)
JP (2) JP7181442B1 (enExample)
KR (2) KR20230169093A (enExample)
CN (1) CN117241817A (enExample)
AU (1) AU2022270498A1 (enExample)
BR (1) BR112023019622A2 (enExample)
CA (1) CA3219090A1 (enExample)
IL (1) IL306018A (enExample)
MX (1) MX2023013099A (enExample)
TW (1) TW202308679A (enExample)
WO (1) WO2022234850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3974563A1 (en) 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides
JP6880352B1 (ja) 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物
EP4086272A1 (en) 2021-05-07 2022-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising n-substituted amino acid residues
CN119731195A (zh) 2022-05-06 2025-03-28 中外制药株式会社 相对于hras和nras对kras具有选择性抑制作用的环状化合物
KR20250088544A (ko) * 2022-10-20 2025-06-17 추가이 세이야쿠 가부시키가이샤 고리형 펩티드 결정을 제조하는 방법
CN120936619A (zh) * 2023-04-20 2025-11-11 中外制药株式会社 用于生产环肽化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112319A1 (en) * 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
WO2012122059A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
EP3974563A1 (en) * 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
JP7232758B2 (ja) 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
US20230096766A1 (en) 2018-12-12 2023-03-30 Chugai Seiyaku Kabushiki Kaisha Amino acid having functional group capable of intermolecular hydrogen bonding, peptide compound containing same and method for production thereof
JP6880352B1 (ja) * 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物
EP4086272A1 (en) * 2021-05-07 2022-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising n-substituted amino acid residues

Also Published As

Publication number Publication date
EP4299069A4 (en) 2025-03-05
TW202308679A (zh) 2023-03-01
BR112023019622A2 (pt) 2023-11-14
JP2023015334A (ja) 2023-01-31
CA3219090A1 (en) 2022-11-10
IL306018A (en) 2023-11-01
AU2022270498A1 (en) 2023-10-05
MX2023013099A (es) 2023-11-17
KR20230020548A (ko) 2023-02-10
JP7181442B1 (ja) 2022-11-30
JPWO2022234850A1 (enExample) 2022-11-10
KR102582225B1 (ko) 2023-09-22
US20240366711A1 (en) 2024-11-07
KR20230169093A (ko) 2023-12-15
EP4299069A1 (en) 2024-01-03
WO2022234850A1 (ja) 2022-11-10

Similar Documents

Publication Publication Date Title
CN117241817A (zh) 包含环状肽化合物的制剂及其制备方法
AU2022259781B2 (en) Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide
EP2310363B1 (en) Anticancer oral formulation
EP2275419B1 (en) A lubiprostone crystal, its preparation process and its use
EP4031133B1 (en) Pyruvate kinase r (pkr) activating compositions
EP3502105A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EA027869B1 (ru) Стабилизированная композиция такролимуса
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
EP3719014A1 (en) Solid forms of an akt inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof
EA039449B1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
CN105801568B (zh) 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
CN103509001B (zh) 一种埃索美拉唑镁三水合物及其制备方法
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
CN112933049B (zh) 含无定型态芳杂环化合物的组合物、其制备方法及用途
WO2019149262A1 (zh) Sb-939的晶型及其制备方法和用途
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
WO2021055863A1 (en) Pyruvate kinase r (pkr) activating compositions
CN113372332B (zh) 一种奥希替尼新晶型
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
TW202521542A (zh) 晶體、藥物組合物及其製備方法和應用
WO2025240802A1 (en) Novel compositions, devices and methods
WO2019137027A1 (zh) Galunisertib的晶型及其制备方法和用途
WO2018209667A1 (zh) 多环杂环化合物的晶型、其制备方法、应用及组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096081

Country of ref document: HK